Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B (China)

August 10, 2023 updated by: Gilead Sciences

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg Positive, Chronic Hepatitis B

The primary objective of this study is to compare the efficacy, safety, and tolerability of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in treatment-naive and treatment-experienced adults with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B virus (HBV) infection in China.

Study Overview

Detailed Description

This study GS-US-320-0110 is an international study planned to enroll participants in global countries, including China. However, due to the review timeline difference in China, full enrollment was reached in the main study (NCT01940471) before China was able to participate. Therefore, this registration only includes the China cohorts as they were not part of the main study analysis. Data for China cohorts were analyzed separately after the main study analysis.

Study Type

Interventional

Enrollment (Actual)

181

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Beijing, China, 100069
        • Beijing Youan Hospital, Capital Medical University
      • Beijing, China, 100050
        • Beijing Friendship Hospital, Capital Medical University
      • Beijing, China, 100015
        • Beijing Ditan Hospital
      • Beijing, China, 100039
        • PLA 302 Hospital
      • Changsha, China, 410008
        • Xianya Hospital, Central South University
      • Guangzhou, China, 510060
        • Guangzhou Eighth People's Hospital
      • Guangzhou, China, 510515
        • Nanfang Medical University, Nanfang Hospital
      • Guangzhou, China, 510630
        • No. 3 Hospital, Zhongshan Medical University
      • Guiyang, China, 550004
        • The affiliated Hospital of Guiyang Medical College
      • Haikou, China, 570311
        • The People's Hospital of Hainan Province
      • Hunan, China, 410011
        • The second Xiangya Hospital of Central South University
      • Jiangsu, China, 210029
        • Jiangsu Province People's Hospital
      • Jiangxi, China, 330006
        • The First Affiliated Hospital of NanChang University
      • Jilin, China, 130021
        • 1st Hospital Jilin University
      • Jinan, China, 250021
        • Jinan Infectious Disease Hospital
      • Nanjing, China, 210003
        • 2nd Hospital of Nanjing City
      • Shanghai, China, 200025
        • Ruijin Hospital, JiaoTong University School of Medicine
      • Shanghai, China, 200083
        • Shanghai Public Health Clinical Center
      • Shanghai, China, 200235
        • 85 Hospital of People's Liberation Army
      • Shenyang, China, 110004
        • Shengjing Hospital of China Medical University
      • Shenyang, China, 110006
        • The Sixth People's Hospital of Shenyang
      • Shijiazhuang, China, 050051
        • 3rd Hospital of Hebei Medical University
      • Sichuan, China, 610041
        • West China Hospital, Sichuan University
      • Xi'an, China, 710061
        • First Affiliated Hospital of Xi'an JiaoTong University
      • Yunnan, China, 650032
        • 1st Affiliated Hospital Kunming Medical College

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Key Inclusion Criteria:

  • Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
  • Adult males and non-pregnant, non-lactating females
  • Documented evidence of chronic HBV infection
  • HBeAg-positive, chronic hepatitis B with all of the following:

    • HBeAg-positive at screening
    • Screening HBV DNA ≥ 2 x 10^4 IU/mL
    • Screening serum alanine aminotransferase (ALT) level > 60 U/L (males) or > 38 U/L (females) and ≤ 10 x the upper limit of the normal range (ULN)
  • Treatment-naive participants (defined as < 12 weeks of oral antiviral treatment with any nucleoside or nucleotide analogue) OR treatment-experienced participants (defined as participants meeting all entry criteria [including HBV DNA and serum ALT criteria] and with ≥ 12 weeks of previous treatment with any nucleoside or nucleotide analogue)
  • Previous treatment with interferon (pegylated or non-pegylated) must have ended at least 6 months prior to the baseline visit
  • Adequate renal function
  • Normal ECG

Key Exclusion Criteria:

  • Females who are breastfeeding
  • Males and females of reproductive potential who are unwilling to use an "effective", protocol specified method(s) of contraception during the study
  • Co-infection with hepatitis C virus, HIV, or hepatitis D virus
  • Evidence of hepatocellular carcinoma
  • Any history of, or current evidence of, clinical hepatic decompensation
  • Abnormal hematological and biochemical parameters, including aspartate aminotransferase (AST) > 10 x ULN
  • Received solid organ or bone marrow transplant
  • History of malignancy within the past 5 years, with the exception of specific cancers that are cured by surgical resection; individuals under evaluation for possible malignancy are not eligible
  • Currently receiving therapy with immunomodulators (eg, corticosteroids), investigational agents, nephrotoxic agents, or agents capable of modifying renal excretion
  • Individuals receiving ongoing therapy with drugs not to be used with tenofovir alafenamide or tenofovir disoproxil fumarate or individuals with a known hypersensitivity to study drugs, metabolites, or formulation excipients
  • Current alcohol or substance abuse judged by the investigator to potentially interfere with participant compliance
  • Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the participant unsuitable for the study or unable to comply with dosing requirements

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: TAF
TAF + TDF placebo for up to 144 weeks
TAF 25 mg tablet administered orally once daily
Other Names:
  • Vemlidy®
  • GS-7340
TDF placebo tablet administered orally once daily
Active Comparator: TDF
TDF + TAF placebo for up to 144 weeks
TDF 300 mg tablet administered orally once daily
Other Names:
  • Viread®
TAF placebo tablet administered orally once daily
Experimental: Open-label TAF
All participants who complete the double-blind period will be eligible to receive open-label TAF until Week 384 of the study.
TAF 25 mg tablet administered orally once daily
Other Names:
  • Vemlidy®
  • GS-7340

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Percentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL at Week 48
Time Frame: Week 48
Week 48

Secondary Outcome Measures

Outcome Measure
Time Frame
Percentage of Participants With Hepatitis B e Antigen (HBeAg) Seroconversion to Antibody Against Hepatitis B e Antigen (Anti-HBe) at Week 48
Time Frame: Week 48
Week 48
Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48
Time Frame: Baseline; Week 48
Baseline; Week 48
Percent Change From Baseline in Spine BMD at Week 48
Time Frame: Baseline; Week 48
Baseline; Week 48
Change From Baseline at Week 48 in Serum Creatinine
Time Frame: Baseline; Week 48
Baseline; Week 48

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of Participants With Treatment-emergent Proteinuria by Urinalysis (Dipstick) Through Week 48
Time Frame: Up to 48 weeks
Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method.
Up to 48 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Gilead Study Director, Gilead Sciences

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 19, 2015

Primary Completion (Actual)

December 15, 2016

Study Completion (Actual)

July 13, 2023

Study Registration Dates

First Submitted

July 14, 2016

First Submitted That Met QC Criteria

July 14, 2016

First Posted (Estimated)

July 18, 2016

Study Record Updates

Last Update Posted (Actual)

August 29, 2023

Last Update Submitted That Met QC Criteria

August 10, 2023

Last Verified

August 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy#Commitment

IPD Sharing Time Frame

18 months after study completion

IPD Sharing Access Criteria

A secured external environment with username, password, and RSA code.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on HBV

Clinical Trials on TAF

3
Subscribe